Greater drop in LDL seen with atorvastatin plus PCSK9 antibody

November 2, 2012
Greater drop in LDL seen with atorvastatin + PCSK9 antibody
Addition of the fully human serum proprotein convertase subtilisin/kexin 9 monoclonal antibody, SAR236553, to atorvastatin is associated with greater reductions in low-density lipoprotein cholesterol levels compared with atorvastatin alone, according to a study published online Oct. 31 in the New England Journal of Medicine.

(HealthDay)—Addition of the fully human serum proprotein convertase subtilisin/kexin 9 monoclonal antibody, SAR236553, to atorvastatin is associated with greater reductions in low-density lipoprotein (LDL) cholesterol levels compared with atorvastatin alone, according to a study published online Oct. 31 in the New England Journal of Medicine.

Eli M. Roth, M.D., from the Sterling Research Group in Cincinnati, and colleagues performed a phase 2 trial involving 92 patients with ≥100 mg/dL after at least seven weeks of treatment with 10 mg . Participants were randomized to three groups to receive eight weeks of 10 or 80 mg daily atorvastatin, plus SAR236553 once every two weeks, or eight weeks of 80 mg atorvastatin with placebo once every two weeks.

The researchers found that there was a significantly greater least-squares mean percent reduction from baseline in LDL cholesterol for treatment with 80 mg atorvastatin plus SAR236553 (73.2 ± 3.5) compared with 10 mg atorvastatin plus SAR236553 (66.2 ± 3.5) or atorvastatin plus placebo (17.3 ± 3.5). All patients who received SAR236553 attained an LDL <100 mg/dL, compared with 52 percent of those receiving 80 mg atorvastatin plus placebo. At least 90 percent of patients who received SAR236553 attained LDL levels <70 mg/dL, compared with 17 percent of those who received 80 mg atorvastatin plus placebo.

"In a involving patients with primary hypercholesterolemia, adding SAR236553 to either 10 mg of atorvastatin or 80 mg of atorvastatin resulted in a significantly greater reduction in LDL cholesterol than that attained with 80 mg of atorvastatin alone," the authors write.

The study was funded by Sanofi and Regeneron Pharmaceuticals, both of which manufacture SAR236553; several authors are employed by Sanofi.

Explore further: Antibody injection lowers LDL, adding to effectiveness of statin therapy

More information: Abstract
Full Text

Related Stories

Antibody injection lowers LDL, adding to effectiveness of statin therapy

March 26, 2012
A novel monoclonal antibody identified in a new study dramatically lowered circulating LDL cholesterol by 40 percent to 72 percent, a development with potential to provide a new option for patients who are resistant to cholesterol-lowering ...

Two statin drugs similarly effective in reversing coronary heart disease

November 15, 2011
Maximum doses of Crestor (rosuvastatin) or Lipitor (atorvastatin) are similarly effective in reversing the buildup of cholesterol plaques in the coronary artery walls (atherosclerosis) after 24 months of treatment, according ...

US approves India's Ranbaxy to make generic Lipitor

December 1, 2011
Indian pharmaceutical giant Ranbaxy won US regulatory approval to make the first generic version of cholesterol lowering drug Lipitor, a Pfizer product whose patent expired Wednesday.

Statin alternative looks promising in early trials

March 22, 2012
(HealthDay) -- Administration of REGN727, a monoclonal antibody to proprotein convertase subtilisin/kexin 9 (PCSK9), significantly reduces low-density lipoprotein (LDL) cholesterol levels, according to the results of three ...

Recommended for you

'Human chronobiome' study informs timing of drug delivery, precision medicine approaches

December 13, 2017
Symptoms and efficacy of medications—and indeed, many aspects of the human body itself—vary by time of day. Physicians tell patients to take their statins at bedtime because the related liver enzymes are more active during ...

Estrogen discovery could shed new light on fertility problems

December 12, 2017
Estrogen produced in the brain is necessary for ovulation in monkeys, according to researchers at the University of Wisconsin-Madison who have upended the traditional understanding of the hormonal cascade that leads to release ...

Time of day affects severity of autoimmune disease

December 12, 2017
Insights into how the body clock and time of day influence immune responses are revealed today in a study published in leading international journal Nature Communications. Understanding the effect of the interplay between ...

3-D printed microfibers could provide structure for artificially grown body parts

December 12, 2017
Much as a frame provides structural support for a house and the chassis provides strength and shape for a car, a team of Penn State engineers believe they have a way to create the structural framework for growing living tissue ...

Team identifies DNA element that may cause rare movement disorder

December 11, 2017
A team of Massachusetts General Hospital (MGH) researchers has identified a specific genetic change that may be the cause of a rare but severe neurological disorder called X-linked dystonia parkinsonism (XDP). Occurring only ...

Protein Daple coordinates single-cell and organ-wide directionality in the inner ear

December 11, 2017
Humans inherited the capacity to hear sounds thanks to structures that evolved millions of years ago. Sensory "hair cells" in the inner ear have the amazing ability to convert sound waves into electrical signals and transmit ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.